Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan
Author: Raspagliesi, F
Kusamura, S
Torres, JCC
de Souza, GA
Ditto, A
Zanaboni, F
Younan, R
Baratti, D
Mariani, L
Laterza, B
Deraco, M
Abstract: Aims: We report the effects of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP) in the treatment of advanced/ recurrent epithelial ovarian cancer (EOC) on survival, morbidity and mortality. Patients: Forty EOC patients were studied. Median age was 52.5 years (range: 30-68) and median follow-up 26.1 months (range: 0.3-117.6). Most patients presented advanced disease (stage III/IV). Previous systemic chemotherapy included cisplatin-based, taxol-based or taxol/platinum containing regimens. Results: After the CRS, 33 patients presented no macroscopic residual disease. Five-year overall survival was 15%; the mean overall and progression-free survivals were 41.4 and 23.9 months, respectively. The morbidity, toxicity and mortality rates were 5%, 15% and 0%, respectively. Conclusion: Our results suggest that CRS + IPHP merits further evaluation by a formal prospective trial. (C) 2006 Elsevier Ltd. All rights reserved.
Subject: advanced ovarian cancer
locoregional therapy
Country: Inglaterra
Editor: Elsevier Sci Ltd
Citation: Ejso. Elsevier Sci Ltd, v. 32, n. 6, n. 671, n. 675, 2006.
Rights: fechado
Identifier DOI: 10.1016/j.ejso.2006.03.011
Date Issue: 2006
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000239920300016.pdf121.35 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.